Company Encyclopedia
View More
name
Quoin Pharmaceuticals
QNRX.US
Quoin Pharmaceuticals, Ltd., a late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company’s lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). It also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat Netherton Syndrome; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc.
1.946 T
QNRX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    U.S. Stock Market Movement Update: Lion surges 69%, Quoin Pharmaceuticals leads the decline at 21%

    Market Overview of US Stocks in the Last Hour Market sentiment fluctuated between the technology and pharmaceutical sectors, with a clear preference shift in capital flows. Lion Holdings led with an astonishing increase, attracting significant attention from short-term funds. Meanwhile, Kala Pharmaceuticals also performed well in the pharmaceutical sector, indicating sustained interest in medical themes. Overall, the market pace is fast, with significant volatility, and short-term enthusiasm continues to rise. The stock with the largest movement in the last hour, Lion Holdings, became the market focus with a 69.41% increase, and the speed and strength of capital inflow are noteworthy. The strong performance of this stock seems to be driven by some theme or news, with short-term sentiment running high, attracting a large amount of speculative capital. Strong Stocks 1. Kala Pharmaceuticals: up 8.92%, benefiting from the continued activity in the pharmaceutical sector, with noticeable capital inflow. 2. Coherent Corp.: up 4.02%, supported by increased demand in the optoelectronics field, with heightened market attention. Under Pressure Stocks 1. Quoin Pharmaceuticals: down 21.15%, with intensified differentiation in the pharmaceutical sector and noticeable capital outflow. 2. Hewlett Packard Enterprise: down 9.17%, pressured by volatility in the technology sector, with market sentiment leaning towards caution. 3. SoFi Tech: down 5.84%, with intensified competition in the fintech sector and signs of capital outflow

    Tracking Unusual Activity·
    US
    LGHL
    -15.77%
    US
    QNRX
    +6.09%
    US
    HPE
    +2.88%
    Tracking Unusual Activity·
    US
    LGHL
    -15.77%
    US
    QNRX
    +6.09%
    US
    HPE
    +2.88%

    U.S. Stock Market Midday Update: Financial announcements trigger stock price surge, analyst ratings fail to stop Quoin Pharmaceuticals' upward momentum

    Quoin Pharmaceuticals rose 12.46%; Olema Pharmaceuticals rose 152.82%, with a trading volume of USD 1.802 billion; AbbVie rose 0.38%, with a trading volume of USD 830 million; Amgen rose 0.85%, with a trading volume of USD 557 million; Gilead Sciences rose 1.77%, with a market capitalization of USD 156.7 billion

    Tracking Unusual Activity·
    US
    QNRX
    +6.09%
    Tracking Unusual Activity·
    US
    QNRX
    +6.09%

    Quoin Pharmaceuticals Unveils New Equity Incentive Plan for Executives and Directors

    Quoin Pharmaceuticals Ltd. has approved new stock option award agreements for directors and executives under its 2025 Equity Incentive Plan. The agreements allow options to be exercised through various payment methods. Unvested awards are forfeited upon termination, while vested awards can be exercised for a limited time after death, disability, or termination. All awards are forfeited immediately upon termination for cause. This information was published via EDGAR by Quoin Pharmaceuticals.

    Reuters·
    US
    QNRX
    +6.09%
    Reuters·
    US
    QNRX
    +6.09%

    Promising Prospects for Quoin Pharmaceuticals: Buy Rating Backed by Innovative Developments and Pipeline Diversification

    Naz Rahman from Maxim Group reiterated a Buy rating on Quoin Pharmaceuticals with a $70.00 price target. The rating is based on Quoin's promising developments, including QRX003 in Phase 3 trials for Netherton Syndrome, and progress with their topical rapamycin formulation. Planned studies for microcystic lymphatic malformation and venous malformation further diversify their pipeline. Rahman has an average return of -9.3% and a 33.33% success rate on recommended stocks.

    Tip Ranks·
    US
    QNRX
    +6.09%
    Tip Ranks·
    US
    QNRX
    +6.09%

    U.S. stock night trading volatility: Quoin Pharmaceuticals' innovative drug delivery technology couldn't prevent a night drop of 8.27% in stock price, market sentiment remains cautious

    Quoin Pharmaceuticals fell 8.27% in after-hours trading; BeiGene rose 0.28% in after-hours trading, with a transaction volume of USD 1.84 million; Korro Bio fell 78.20% in after-hours trading, with a transaction volume of USD 785,500; Recursion Pharmaceuticals rose 0.22% in after-hours trading, with a transaction volume of USD 174,300

    Tracking Unusual Activity·
    US
    QNRX
    +6.09%
    Tracking Unusual Activity·
    US
    QNRX
    +6.09%
    © 2025 Longbridge｜Disclaimer